Liver/Biliary Disorders News

Increased hepatic steatosis was observed among responders who arrived earlier at the World Trade Center site, according to a study published in American Journal of Industrial Medicine.

Combined serum circulating micro-RNA served as a novel biomarker for the diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease, according to research published in Nature Scientific Reports.

For patients with severe COVID-19, cholangiopathy was a late complication with potential for progressive biliary injury or liver failure, according to a study published in the American Journal of Gastroenterology.

Healio Gastroenterology presents the following reports on recent news in COVID-19.

Liver transplant candidates with decompensated cirrhosis who were infected with COVID-19 had increased mortality during the first and second waves of the pandemic, according to data published in Gut.

Albiero Pharma Inc. announced it received FDA approval for Bylvay to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis.

Terns Pharmaceuticals Inc. announced initiation of a phase 1b clinical trial assessing TERN-201 for the treatment of patients with nonalcoholic steatohepatitis.

The FDA’s Gastroenterology and Urology Devices Panel, Medical Devices Advisory Committee voted unanimously that a portable system for near-normothermic continuous perfusion of donor livers with perfusate was safe and effective.

Treating patients who have primary biliary cholangitis and cirrhosis with seladelpar — a peroxisome proliferator-activated receptor agonist — led to improved liver biochemistries and improved pruritus scores, according to a presenter at the International Liver Congress.

Axcella announced initiating patient screening for the EMMPOWER phase 2 clinical trials of AXA1665 for reduction in risk for recurrent overt hepatic encephalopathy, according to a press release.